3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 1
1
Status
Recruiting
1
Active not recruiting
1
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
NET
2
Endocrine
2
Sarcoma
1
Lymphoid
1
Gastrointestinal
1
CNS
1
Conditions
Neuroendocrine Tumors
2
Rhabdomyosarcoma
1
Neuroectodermal Tumors, Primitive, Peripheral
1
Lymphoma
1
Gastro-enteropancreatic neuroendocrine tumor
1
Central Nervous System Neoplasms
1
Interventions
pembrolizumab
302
Carboplatin
230
Cisplatin
159
Paclitaxel
153
Gemcitabine
153
Pemetrexed
122
Bevacizumab
121
Docetaxel
105
durvalumab
83
Oxaliplatin
82
Nivolumab
82
Dexamethasone
80
atezolizumab
79
Fluorouracil
79
Cyclophosphamide
79
130-nm albumin-bound paclitaxel
74
Fulvestrant
72
Capecitabine
67
Injections
66
Cetuximab
64
Leucovorin
63
Rituximab
57
fludarabine
52
Lenalidomide
51
venetoclax
47
Prednisone
45
Irinotecan
42
enzalutamide
41
Letrozole
41
tislelizumab
38
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
INDUSTRY
×
amino-acid, glucose, and electrolyte solution
×
90 days
×
Clear all
NCT06441331
2026-05-01
KinLET
ITM Solucin GmbH
Phase 1
Recruiting
20 enrolled
NCT03049189
2026-04-06
COMPETE
ITM Solucin GmbH
Phase 3
Active not recruiting
324 enrolled
15 charts